Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with HER2 expression.

Kitadai, Rui; Nishikawa, Tadaaki; Yoshida, Hiroshi; Mizoguchi, Chiharu; Yamamoto, Kasumi; Kato, Tomoyasu; Yonemori, Kan

Kitadai, Rui; Nishikawa, Tadaaki; Yoshida, Hiroshi; Mizoguchi, Chiharu; Yamamoto, Kasumi; Kato, Tomoyasu; Yonemori, Kan.

Afiliação

Kitadai R; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Nishikawa T; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Yoshida H; Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan.
Mizoguchi C; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Yamamoto K; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
Kato T; Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan.
Yonemori K; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. kyonemor@ncc.go.jp.

J Gynecol Oncol ; 35(2): e11, 2024 Mar.

Article em En | MEDLINE | ID: mdl-37914528

Assuntos

Carcinossarcoma; Neoplasias Ovarianas; Neoplasias Uterinas; Humanos; Feminino; Mesotelina; Estudos Retrospectivos; Neoplasias Uterinas/patologia; Neoplasias Ovarianas/patologia; Carcinossarcoma/patologia

Palavras-chave

Human Epidermal Growth Factor Receptor 2; Immunohistochemistry; Mesothelin; Ovarian Carcinosarcoma; Prognosis; Uterine Carcinosarcoma

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ovarianas / Neoplasias Uterinas / Carcinossarcoma Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google